Navigation Links
The Alzheimer's Disease Market Is Forecast to Reach Nearly $12 Billion by 2023, Following the Projected Launch of the First Disease-Modifying Therapies
Date:7/21/2014

BURLINGTON, Mass., July 21, 2014 /PRNewswire/ -- Decision Resources Group finds that the market for Alzheimer's disease (AD) therapies will more than triple, reaching nearly $12 billion by 2023, owing largely to the forecasted launch of the first disease-modifying therapies (DMTs), a landmark event in AD treatment. In 2023, these novel premium-priced agents—which include the anti-beta-amyloid monoclonal antibodies solanezumab (Eli Lilly) and gantenerumab (Roche), as well as the BACE inhibitor MK-8931 (Roche/Chugai/MorphoSys)—will earn sales of $7 billion combined in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.

Other key findings from the Pharmacor report entitled Alzheimer's Disease:

  • A new symptomatic alternative: Lundbeck/Otsuka's novel 5HT-6 receptor antagonist, Lu-AE58054, will launch as an adjunctive symptomatic treatment for AD and achieve blockbuster sales within the forecast period, capturing nearly 10 percent of major-market sales in 2023.
  • Population growth: The surging prevalence of AD as the population ages will drive growth across the major markets. We also expect diagnosis and drug-treatment rates to rise modestly in the pre-AD 1-2 years* and mild AD patient segments as DMTs and new diagnostic technologies gradually gain traction.
  • Current agents stay relevant: Today's clinical mainstays deliver modest symptomatic efficacy and do not affect disease progression but will remain the foundation of treatment throughout the forecast period—aided in part by growing generic availability. We forecast that acetylcholinesterase inhibitors (AChEIs) will continue to capture over 70 percent total patient share (across all AD subpopulations) in 2023, while NMDA receptor antagonist products, including Forest's Namenda/Namenda XR, will continue to capture approximately 35 percent patient share.

Comments from Decision Resources Group Analyst Alana Simorellis, Ph.D.:

  • "The projected launch of Eli Lilly's solanezumab, potentially the first ever DMT approved for the treatment of AD, will be a transformative event affecting the AD market as early as 2018. Commensurate with ongoing development and the views of experts in the field, we expect that future DMTs will most likely see the greatest uptake in the pre-AD and mild AD populations. Moreover, experts interviewed note that new symptomatic options also are sorely needed. Lundbeck/Otsuka's Lu-AE58054 and potentially others could partially address this need beginning in 2017."
  • "While AD drug development is understandably focused on disease modification, there exists an important area of additional unmet need for safer, more-effective symptomatic therapies that can control the behavior disturbances associated with later-stage AD. Development in this arena is underway, with clinical trials assessing promising agents like Lundbeck/Otsuka's brexpiprazole for AD-associated agitation."

*Decision Resources Group defines its proprietary pre-AD 1-2 years population as those patients who will go on to develop AD within the next one to two years.

About Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597 
ccomfort@dresourcesgroup.com

Logo - http://photos.prnewswire.com/prnh/20130103/MM36768LOGO


'/>"/>

SOURCE Decision Resources Group
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Amgen Announces Positive Phase 3 Results for AMG 416 for the Treatment of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease Receiving Hemodialysis
2. FDA Grants Astellas Qualified Infectious Disease Product Designation for Isavuconazole for the Treatment of Invasive Candidiasis
3. New Study Shows Beta-Amyloid Imaging is Associated with Altered Diagnosis and Management of Alzheimers Disease
4. New Data Shows Cognitive Impairment Precedes and Predicts Subsequent Functional Impairment in Patients with Mild Alzheimers Disease
5. aTyr Pharma Announces Publication of a Rare Muscle Disease Associated with Regulation of a Potential Physiocrine
6. Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease
7. Pain Management Medical Journal Features BioElectronics Innovative Pain Products Because Pain is Not a Druggable Disease
8. Akili Interactive Labs Announces Partnership with Pfizer to Test Video Game in People at Risk of Alzheimers Disease
9. Liver Diseases Therapeutics Market (Chemotherapy, Anti-Virals, Vaccines, Targeted Therapy and Immunosuppressants) - Global Industry Analysis, Size, Share, Trends and Forecast, 2012 - 2018
10. Asleep During Brain Surgery: A Comfortable Alternative for Patients with Parkinsons Disease
11. Shield Therapeutics ST10 Delivers Robust Results Meeting both Primary and Secondary Endpoints in the Pivotal AEGIS Phase 3 Programme for the Treatment of Iron Deficiency Anaemia in Inflammatory Bowel Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... SPRINGS, Florida , May 25, 2016 ... Business Conference & Expo earlier this month, the numbers ... As revenues continue to climb into the billions, more ... the newly released 4th Edition State of Legal Marijuana ... Frontier, a cannabis-focused data-analysis firm, much of the increase ...
(Date:5/25/2016)... , May 25, 2016 Digital Health ... to it by the US Patent and Trademark ... technology includes proprietary processes for electronic opt-­in and ... and wellness programs, HIPAA compliance and otherwise. ... "Our technology allows for ...
(Date:5/25/2016)... , May 25, 2016 ... the precision of circulating tumour DNA (ctDNA) analysis ... the appointment of Professor Clive Morris ... leadership across the clinical development programme, scientific collaborations, ... help deliver significant improvements in clinical outcomes for ...
Breaking Medicine Technology:
(Date:5/28/2016)... ... 28, 2016 , ... May 26, 2016- In search of the K. Warriors, ... event of “K Warriors” on June 4, 2016 at Ashbury Hotel and Suites 600 ... sponsored and hosted by Shaolin Institute and sanctioned by KSF (Kungfu Sanda Federation), This ...
(Date:5/28/2016)... , ... May 28, 2016 , ... In a part of the city where’s it’s ... new farm-to-table Kelowna restaurants is hoping to attract diners with a taste for ... Suites officially opened the doors to Cornerstone Grill, an urban casual restaurant focusing on ...
(Date:5/27/2016)... ... May 27, 2016 , ... Southland Log Homes , designer ... timber frame barn kits, which can be found on its website at SouthlandLogHomes.com. , ... barn plans, and they highlight the craftsmanship of timber post and beam construction. ...
(Date:5/27/2016)... ... May 27, 2016 , ... W.S. Badger Co. ... today that it has been recognized as one of the best small businesses for ... named as one of nine small businesses providing progressive benefits to new parents on ...
(Date:5/27/2016)... ... May 27, 2016 , ... With over 60 percent ... the demand for a sustainable product to aid in the rehabilitation process has steadily ... the recovery of individuals with hemiplegia due to stroke. , Ekso Bionics has now ...
Breaking Medicine News(10 mins):